comparemela.com

Latest Breaking News On - Paula treutiger - Page 1 : comparemela.com

Senzime : Adjusted proposal from the Nomination Committee

N.B. English translation for convenience purposes only. In the event of discrepancies, the Swedish version shall prevail. Senzime s nomination. | May 5, 2023

Uppsala lanVastra gotalands lanLaura piccininiSorin brullAdam dahlbergJenny freemanEva waldeGabriel urwitzPaula treutigerPhilip sibergGothenburg universityElos medtechSenzime ab publ stock exchangePress releaseHall sezi se0002478776

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection).

United statesDietmar bergerAnders ullmanThomas kudsk larsenPaula treutigerDrug administrationSobi investor relations teamGlobal head of development at sanofiAmunix pharmaceuticals incHead of research developmentChief medical officerGlobal headOrphan drug designationEuropean commissionFast track designationNorth africa

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection).

United statesDietmar bergerAnders ullmanThomas kudsk larsenPaula treutigerDrug administrationSobi investor relations teamGlobal head of development at sanofiAmunix pharmaceuticals incHead of research developmentChief medical officerGlobal headOrphan drug designationEuropean commissionFast track designationNorth africa

Swedish Orphan Biovitrum AB: Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)

STOCKHOLM, Feb. 25, 2022 /PRNewswire/ Sobi today announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant to the National Medical Products Administration of

United statesNorbert oppitzThomas kudsk larsenPaula treutigerPrnewswire sobiNational medical products administration of chinaSobi investor relations teamHead of international at sobiDrug evaluationNational medical products administrationTherapeutic approachesNorth americaMiddle eastSobi media

Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)

/PRNewswire/ Sobi® today announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant® to the National Medical Products.

United statesNorbert oppitzThomas kudsk larsenPaula treutigerPrnewswire sobiNational medical products administration of chinaSobi investor relations teamHead of international at sobiDrug evaluationNational medical products administrationTherapeutic approachesNorth americaMiddle eastSobi mediaOrphan biovitrumSwedish orphan biovitrum ab

vimarsana © 2020. All Rights Reserved.